Insider buying
~$2.1K2,500 sh @ $0.8387
Traded Dec 13, 2024 · filed 3 days later
The CEO of Silo Pharma paid $2.1K out of pocket for Silo Pharma shares.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Traded Nov 20, 2024 · Filed Nov 22, 2024
The CEO of Silo Pharma paid $2.4K out of pocket for Silo Pharma shares. It was the first purchase in over a year.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell.
open market purchase
Code P — open-market or private purchase
~$2,375
Shares × reported transaction price
<$25K
+1.4%
Purchase shares ÷ estimated pre-transaction holdings, from the filing
None in 13 months of history
Confirmed open-market purchases by the same insider in the available history
No other insider purchases within 30 days
Distinct insiders at the same issuer with confirmed open-market purchases
This purchase equals less than 1% of the CEO's reported total pay for fiscal 2023 ($569K)
Purchase value ÷ the CEO's total from the Summary Compensation Table, as tagged in the pay versus performance table of the company's proxy statement (DEF 14A), filed 2026-06-30. The proxy does not tag the CEO's name, so the match rests on the Form 4 title only. A size comparison, not a judgement
None found in footnotes
Only flagged when a footnote says so; never inferred
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | +20.6% | +1.0% | +19.5% |
| 30 days | +9.2% | +0.6% | +8.6% |
| 90 days | +49.8% | −0.1% | +49.9% |
| 180 days | −48.9% | −1.1% | −47.8% |
| 365 days | −50.4% | +13.0% | −63.4% |
Past results only. Not a forecast.
Insider buying
Traded Dec 13, 2024 · filed 3 days later
The CEO of Silo Pharma paid $2.1K out of pocket for Silo Pharma shares.
Insider buying
Traded Nov 22, 2024 · filed the same day
The CEO of Silo Pharma paid $2.3K out of pocket for Silo Pharma shares.
Eric Weisblum, CEO and President's past purchases, 90 days after disclosure: 6 buys, median +3.6 pts vs S&P 500, beat it 3 of 6 times. Past results, not a forecast.
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.